Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Oral Mucositis Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Oral Mucositis Overview | 9 | 1 |
| Pipeline Products for Oral Mucositis Comparative Analysis | 10 | 1 |
| Oral Mucositis Therapeutics under Development by Companies | 11 | 1 |
| Oral Mucositis Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Oral Mucositis Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Oral Mucositis Products under Development by Companies | 16 | 1 |
| Oral Mucositis Products under Investigation by Universities/Institutes | 17 | 1 |
| Oral Mucositis Companies Involved in Therapeutics Development | 18 | 11 |
| Aldeyra Therapeutics, Inc. | 18 | 1 |
| Cellceutix Corporation | 19 | 1 |
| Colby Pharmaceutical Company | 20 | 1 |
| Daewoong Pharmaceutical Co., Ltd. | 21 | 1 |
| Galera Therapeutics, Inc. | 22 | 1 |
| Onxeo SA | 23 | 1 |
| Oragenics, Inc. | 24 | 1 |
| Otsuka Holdings Co., Ltd. | 25 | 1 |
| Soligenix, Inc. | 26 | 1 |
| Spectrum Pharmaceuticals, Inc. | 27 | 1 |
| Spherium Biomed S.L. | 28 | 1 |
| Oral Mucositis Therapeutics Assessment | 29 | 9 |
| Assessment by Monotherapy Products | 29 | 1 |
| Assessment by Target | 30 | 2 |
| Assessment by Mechanism of Action | 32 | 2 |
| Assessment by Route of Administration | 34 | 2 |
| Assessment by Molecule Type | 36 | 2 |
| Drug Profiles | 38 | 37 |
| AG-013 Drug Profile | 38 | 2 |
| brilacidin tetrahydrochloride Drug Profile | 40 | 9 |
| clonidine hydrochloride ER Drug Profile | 49 | 3 |
| dusquetide Drug Profile | 52 | 4 |
| GC-4419 Drug Profile | 56 | 2 |
| Gene Therapy for Oral Mucositis Drug Profile | 58 | 1 |
| Gene Therapy for Oral Mucositis Drug Profile | 59 | 1 |
| KIN-219 Drug Profile | 60 | 1 |
| nepidermin Drug Profile | 61 | 1 |
| NS-2 Drug Profile | 62 | 3 |
| pralatrexate Drug Profile | 65 | 6 |
| rebamipide Drug Profile | 71 | 2 |
| Recombinant Protein for Immunology, Dermatology, Oncology and Musculoskeletal Disorders Drug Profile | 73 | 1 |
| SP-13004 Drug Profile | 74 | 1 |
| Oral Mucositis Dormant Projects | 75 | 3 |
| Oral Mucositis Discontinued Products | 78 | 1 |
| Oral Mucositis Product Development Milestones | 79 | 10 |
| Featured News &Press Releases | 79 | 1 |
| Jul 21, 2016: Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis | 79 | 1 |
| Jun 06, 2016: Soligenix Announces Presentation of Phase 2 Oral Mucositis Clinical Trial Results at the 2016 Multinational Association for Supportive Care in Cancer Conference | 79 | 1 |
| Jun 06, 2016: Galera Therapeutics Announces Presentation at ASCO of Positive Results from Study of GC4419 for the Reduction of Severe Oral Mucositis | 80 | 1 |
| May 02, 2016: Oragenics Announces Positive Results from Confirmatory Animal Study of AG013 for Treatment of Oral Mucositis and Plans to Finalize Phase 2 Clinical Trial Protocol | 81 | 1 |
| Apr 14, 2016: Soligenix Announces Issuance of New Patents for Dusquetide | 81 | 1 |
| Jan 07, 2016: Galera Therapeutics Announces Fast Track Designation of GC4419 for Prevention of Oral Mucositis | 82 | 1 |
| Dec 21, 2015: SciClone To Pursue Development Of SGX942 In China Following Soligenix' Report Of Positive Phase 2 Preliminary Results In Oral Mucositis | 83 | 1 |
| Dec 16, 2015: Soligenix Announces Positive Preliminary Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients | 83 | 2 |
| Dec 04, 2015: Soligenix Provides Clinical Program Updates on SGX942 for December 2015 | 85 | 1 |
| Nov 25, 2015: FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis | 85 | 1 |
| Oct 22, 2015: Onxeo Announces Data Demonstrating High Patient Compliance and Acceptability of Validive for Treatment of Severe Oral Mucositis | 85 | 1 |
| Oct 19, 2015: Onxeo Validive Abstract Accepted for Oral Presentation at ASTRO Annual Meeting 2015 | 86 | 1 |
| Sep 09, 2015: Aldeyra Therapeutics to Present Novel Data on a Potential Treatment for Succinic Semi-Aldehyde Dehydrogenase Deficiency at the 2015 American Society of Human Genetics Annual Meeting | 87 | 1 |
| Aug 31, 2015: Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients | 87 | 1 |
| Aug 03, 2015: Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for Oral Mucositis | 88 | 1 |
| Appendix | 89 | 2 |
| Methodology | 89 | 1 |
| Coverage | 89 | 1 |
| Secondary Research | 89 | 1 |
| Primary Research | 89 | 1 |
| Expert Panel Validation | 89 | 1 |
| Contact Us | 89 | 1 |
| Disclaimer | 90 | 1 |